Cantor Fitzgerald: The Mereo BioPharma Group (MREO.US) rating was reaffirmed and adjusted from an increase to an increase in holdings rating, with a target price of $7.00.
坎托菲茨杰拉德公司：重申Mereo BioPharma Group(MREO.US)评级，由增持调整至增持评级, 目标价7.00美元。
Cantor Fitzgerald: The Mereo BioPharma Group (MREO.US) rating was reaffirmed and adjusted from an increase to an increase in holdings rating, with a target price of $7.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated